Skip to content
All Sections
Subscribe Now
61°F
Tuesday, October 8th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Election
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
61°F
Tuesday, October 8th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
4 stabbings in 9 hours
DMV scraps test for some
Marathon road closures ð
Fashion takeback law
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Eisai
< Previous
1
2
Next >
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
December 19, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
December 14, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
December 01, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
November 23, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
April 01, 2022
From
Eisai
Via
ACN Newswire
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
November 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
March 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
March 22, 2022
From
Eisai
Via
ACN Newswire
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
March 15, 2022
From
Eisai
Via
ACN Newswire
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
March 15, 2022
From
Eisai
Via
ACN Newswire
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
February 25, 2022
From
Eisai
Via
ACN Newswire
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
February 01, 2022
From
Eisai
Via
ACN Newswire
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
January 31, 2022
From
Eisai
Via
ACN Newswire
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
January 20, 2022
From
Eisai
Via
ACN Newswire
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
January 17, 2022
From
Eisai
Via
ACN Newswire
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
January 13, 2022
From
Eisai
Via
ACN Newswire
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
January 06, 2022
From
Eisai
Via
ACN Newswire
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
December 24, 2021
From
Eisai
Via
ACN Newswire
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
December 21, 2021
From
Eisai
Via
ACN Newswire
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
December 20, 2021
From
Eisai
Via
ACN Newswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close